362 related articles for article (PubMed ID: 21156036)
1. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
Etcheverry A; Aubry M; de Tayrac M; Vauleon E; Boniface R; Guenot F; Saikali S; Hamlat A; Riffaud L; Menei P; Quillien V; Mosser J
BMC Genomics; 2010 Dec; 11():701. PubMed ID: 21156036
[TBL] [Abstract][Full Text] [Related]
2. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
[TBL] [Abstract][Full Text] [Related]
4. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
7. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
8. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Dunn J; Baborie A; Alam F; Joyce K; Moxham M; Sibson R; Crooks D; Husband D; Shenoy A; Brodbelt A; Wong H; Liloglou T; Haylock B; Walker C
Br J Cancer; 2009 Jul; 101(1):124-31. PubMed ID: 19536096
[TBL] [Abstract][Full Text] [Related]
9. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
10. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
Brigliadori G; Foca F; Dall'Agata M; Rengucci C; Melegari E; Cerasoli S; Amadori D; Calistri D; Faedi M
J Neurooncol; 2016 Jun; 128(2):333-9. PubMed ID: 27029617
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
12. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas.
Michaelsen SR; Aslan D; Urup T; Poulsen HS; Grønbæk K; Broholm H; Kristensen LS
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495584
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.
Shah N; Lin B; Sibenaller Z; Ryken T; Lee H; Yoon JG; Rostad S; Foltz G
PLoS One; 2011 Jan; 6(1):e16146. PubMed ID: 21249131
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
19. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
20. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]